8-K: Marker Therapeutics Initiates Off-the-Shelf T-Cell Program

Marker Therapeutics announced the treatment of the first patient in its Off-the-Shelf (OTS) program for Multi-Antigen Recognizing (MAR)-T cell therapy, showing encouraging preliminary safety data.

Summary

• The first patient has been treated in the company's Off-the-Shelf (OTS) program, evaluating Multi-Antigen Recognizing (MAR)-T cell therapy (MT-401) in the Phase 1 RAPID study (NCT06552416).
• The initial dose level (100x10^6 cells) of the OTS product was well tolerated, with no treatment-related adverse events observed over 28 days, consistent with previous MAR-T cell studies.
• The OTS program aims to overcome limitations of individualized cell therapy by providing a faster treatment option, potentially within 72 hours, using commercially available leukapheresis material from healthy donors.
• The MT-401 OTS product targets four tumor antigens (Survivin, PRAME, NY-ESO-1, WT-1) and is initially being tested in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
• Non-dilutive funding from the FDA, NIH Small Business Innovation Research (SBIR) program, and the Cancer Prevention and Research Institute of Texas (CPRIT) supports the OTS program, preserving the company's financial runway.
• The company continues to advance its lead asset, MT-601, in the Phase 1 APOLLO study for lymphoma, which recently reported a 66% objective response rate with durable complete responses in non-Hodgkin lymphoma patients.

Sentiment

Score: 8

Explanation: The announcement of the first patient treated in the Off-the-Shelf program, coupled with encouraging preliminary safety data and non-dilutive funding, represents a significant positive step for the company. The strategic focus on scalability and cost-effectiveness, alongside continued positive results from the lymphoma program, indicates strong operational progress and potential for future growth, despite the early stage of the OTS trial.

Positives

• Achieved a significant clinical milestone with the first patient treated in the Off-the-Shelf (OTS) program.
• Preliminary safety data for the OTS product (MT-401) is encouraging, showing it was well tolerated with no treatment-related adverse events at the initial dose (100x10^6 cells).
• The OTS approach aims to provide faster treatment (potentially 72 hours), broader scalability, and lower per-dose costs, addressing key limitations of current cell therapies.
• Secured non-dilutive funding from the FDA, NIH SBIR, and CPRIT for the OTS program, which supports its advancement without impacting the company's financial runway.
• Reported promising clinical efficacy and durability data from the APOLLO study for MT-601 in non-Hodgkin lymphoma, with a 66% objective response rate and durable complete responses, suggesting potential for expedited approval.
• Established a cellular inventory from commercially available leukapheresis material, validated by prior clinical studies, to cover a large patient population with partially HLA-matched material.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those stated.
• Risks related to the effectiveness of research, development, and regulatory activities and expectations concerning non-engineered multi-tumor antigen specific T cell therapies.
• Uncertainties regarding the possible range of application, potential curative effects, and safety in the treatment of diseases.
• Risks associated with the timing, conduct, interim results announcements, and outcomes of clinical trials for product candidates, including MT-601 and MT-401-OTS.
• General risks outlined in the company's most recent Form 10-K, 10-Q, and other SEC filings.

Future Outlook

The company will remain focused on advancing its clinical investigation of MAR-T cells in lymphoma, believing the program has the potential to qualify for expedited approval. It will continue to closely monitor the safety and long-term treatment effects of the OTS product as additional patients are enrolled in the Phase 1 RAPID study. The collected data will serve as a foundation for refining and understanding the performance of MAR-T cells as an OTS product, with the goal of potentially expanding this approach to other product candidates in the pipeline to accelerate time to treatment in other indications.

Management Comments

• "The initiation of our OTS program represents a major achievement." Juan Vera, M.D., President and CEO of Marker Therapeutics.
• "One of the biggest limitations to cell therapy is the time-consuming manufacturing of individualized products. With our OTS product, we are aiming to remove this bottleneck and provide a fast treatment option for patients with aggressive and rapidly progressing diseases." Juan Vera, M.D., President and CEO.
• "We believe that using commercially available leukapheresis material from healthy donors can facilitate large-scale manufacturing and expedite treatment as fast as 72 hours, while also enabling broader scalability and accessibility of cell therapies at a lower per-dose cost." Juan Vera, M.D., President and CEO.
• "Having a rapid available alternative to individualized T cell production allows us to broaden our clinical investigation of MAR-T cells and to extend the OTS program to other indications." Juan Vera, M.D., President and CEO.
• "We recently reported promising clinical efficacy and durability data from our APOLLO study where we have observed an objective response rate of 66%, with durable complete responses in patients with non-Hodgkin lymphoma, and we believe our lymphoma program has the potential to qualify for expedited approval." Juan Vera, M.D., President and CEO.
• "As we enroll additional patients in the Phase 1 RAPID study, we will continue to closely monitor the safety and long-term treatment effects of our OTS product." Juan Vera, M.D., President and CEO.

Industry Context

The development of "Off-the-Shelf" (allogeneic) cell therapies by Marker Therapeutics addresses a critical industry challenge: the time-consuming and costly manufacturing of individualized (autologous) cell therapy products. This strategic move aligns with a broader industry trend towards creating more scalable, accessible, and rapidly deployable cell therapies, aiming to expand the reach of advanced immunotherapies. The company's focus on a non-genetically modified, multi-antigen recognizing T cell platform also positions it to potentially overcome limitations such as tumor escape and high manufacturing costs associated with some existing engineered T cell approaches.

Comparison to Industry Standards

• The "Off-the-Shelf" approach using commercially available leukapheresis material aims to significantly reduce the typical 2-4 week manufacturing time for autologous CAR-T cell therapies (e.g., Novartis' Kymriah, Gilead/Kite Pharma's Yescarta), potentially expediting treatment to as fast as 72 hours.
• The non-genetically modified MAR-T cell platform is presented as potentially easier and less expensive to manufacture with an improved safety profile compared to current engineered T cell approaches (e.g., CAR-T, TCR-T), which often involve complex genetic modification and associated costs/risks.
• The multi-antigen recognition (targeting four antigens for MT-401) aims to reduce the possibility of tumor escape, a known limitation in single-target therapies, by recognizing hundreds of different epitopes. This contrasts with some single-target CAR-T therapies that can face resistance due to antigen loss.
• The 66% objective response rate with durable complete responses in non-Hodgkin lymphoma from the APOLLO study for MT-601 is a strong indicator, comparable to or exceeding some reported rates for approved CAR-T therapies in similar indications, though direct comparison requires full trial data and context.

Stakeholder Impact

• Shareholders: Positive impact due to clinical progress, potential for accelerated development, and non-dilutive funding preserving capital. Increased confidence in the company's pipeline and strategic direction.
• Patients (AML/MDS): Potential for a faster, more accessible, and potentially safer treatment option for aggressive and rapidly progressing diseases.
• Healthcare Providers: Potential for a more scalable and cost-effective cell therapy option, simplifying logistics compared to individualized products.
• Employees: Positive impact from achieving significant clinical milestones and securing funding, indicating job security and progress.

Next Steps

• Enroll additional patients in the Phase 1 RAPID study for the OTS product.
• Closely monitor the safety and long-term treatment effects of the OTS product.
• Collect data from the RAPID trial to inform future clinical developments and guide potential use of MAR-T cells as an OTS product in other indications.
• Advance clinical investigation of MAR-T cells in lymphoma (APOLLO study).
• Potentially expand the OTS approach to other product candidates in the pipeline.

Key Dates

Recommendation

While the news is positive, representing a significant clinical milestone and strategic advancement, the Off-the-Shelf program is still in Phase 1, and the company's lead asset (MT-601) is also in Phase 1. The long development timelines and inherent risks of clinical-stage biotechnology companies warrant a 'hold' recommendation for seasoned investors. The non-dilutive funding is a strong positive, mitigating immediate capital raise concerns, but further clinical data and progression through later-stage trials are needed to justify a 'buy' recommendation. The promising APOLLO data is encouraging but still early.

Keywords

Marker Therapeutics, MRKR, Off-the-Shelf, OTS, MAR-T cell therapy, immuno-oncology, AML, MDS, lymphoma, clinical trial, Phase 1 RAPID, MT-401, MT-601, cell therapy, biotechnology, oncology, FDA, NIH, CPRIT